Jose Luis Vazquez Martinez

Brenipatide for Substance Use Disorders: Current Evidence at a Glance (September 2026)

Jose Luis Vazquez Martinez -

Source:https://sin-adiccion.blogspot.com/2026/09/brenipatide-brenipatida.html

Given the current state of the evidence, brenipatide should not replace approved or guideline-recommended treatments for alcohol, opioid, or tobacco use disorders outside the context of a clinical trial.

 

References / Referencias

  • Cai, M., Choi, T., Xie, Y., & Al-Aly, Z. (2026). Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: Cohort study. BMJ, 392, e086886. https://doi.org/10.1136/bmj-2025-086886 [pubmed.ncb...lm.nih.gov]
  • Patil, S., Jha, N., & Jha, M. K. (2026). Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.gov. Addictive Behaviors Reports, 23, 100671. https://doi.org/10.1016/j.abrep.2026.100671 [pubmed.ncb...lm.nih.gov]
  • Sarma, I., Biswas, K. P., Jagdish, P., Praveen, K., Ahmed, K. A., & Saikia, D. (2026). A systematic review and meta-analysis evaluating the role of GLP-1 receptor agonists in substance use disorders. Cureus, 18(6), e111641. https://doi.org/10.7759/cureus.111641 [pubmed.ncb...lm.nih.gov][pmc.ncbi.nlm.nih.gov]
  • Völker, K. M., Prechtl, B. L. H., Bormann, N. L., & Choi, D. S. (2026). The potential role of GLP-1 receptor agonists in substance use disorders: A systematic review. Frontiers in Pharmacology, 16, 1702448. https://doi.org/10.3389/fphar.2025.1702448 [frontiersin.org][doaj.org]

 

Clinical trial records / Registros de ensayos clínicos